- Home
- SMBK vs SGP Comparison
SMBK vs SGP Comparison
Compare SMBK & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SMBK | SGP |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.9M | 910.8M |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SMBK | SGP |
|---|---|---|
| Price | $51.04 | $26.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $43.17 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 110.8K | 63.6K |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 39.25 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.59 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | $28.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.01 | $17.06 |
| 52 Week High | $54.14 | $30.56 |
Technical Indicators
Market Signals| Indicator | SMBK | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 66.55 |
| Support Level | $50.93 | $25.25 |
| Resistance Level | $53.71 | $29.11 |
| Average True Range (ATR) | 1.16 | 1.38 |
| MACD | -0.42 | 0.12 |
| Stochastic Oscillator | 27.14 | 77.09 |
Price Performance
Historical ComparisonAbout SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.